Dario Trapani, Medical Oncologist at European Institute of Oncology (IEO), Researcher at Department of Oncology and Hemato-Oncology at University of Milan, shared a post on LinkedIn:
“The new ESMO EnLiST framework is here to provide much-needed clarity. This consensus framework standardizes the designation of systemic therapy lines in solid tumors.
Key Takeaways:
- Uniform definitions for ‘line of therapy’ across clinical practice and research.
- Guidance on navigating complex scenarios (maintenance, switches due to toxicity vs. progression).
- Improved consistency for real-world evidence and clinical trial endpoints.
A vital step toward better data integration and clearer treatment sequencing.”
Title: ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
Authors: K. Saini, M. Koopman, D. Martins-Branco, P. Bossi, S. Braendegaard, M. Brahmi, I. Braña, E. Calvo, L. Castelo-Branco, I. Colombo, E. de Azambuja, D. De Ruysscher, R. Dienstmann, A. Dingemans, M. Ekholm, C. Gallois, V. Golfinopoulos, E. Grande, S. Halabi, E. Le Rhun, O. Le Saux, N. Leighl, S. Lonardi, S. Lorenzen, D. Lorusso, G. Minniti, G. Mountzios, J. Oldenburg, S. Oosting, P. Osterlund, J. Perez-Gracia, A. Pellat, S. Piperno-Neumann, R. Plummer, C. Porta, K. Punie, I. Ray-Coquard, J. Remon, C. Ruhlmann, P. Rutkowski, L. Siu, S. Stacchiotti, C. Suarez, K. Suijkerbuijk, J. Taieb, D. Trapani, A. Valachis, H. van Laarhoven, A. Vogel, A. Zer, G. Pentheroudakis, S. Delaloge, C. Twelves
Read the Full Article.
Other articles featuring Dario Trapani.